EOG
62
6
HIG
54
-8
AES
46
2
AAL
16
-13
CAT
55
-2
PH
60
-2
MDLZ
34
4
SJM
19
2
D
58
5
CINF
58
3
O
48
-14
IR
35
-3
MKC
38
2
PNC
59
3
L
67
3
KIM
50
13
ISRG
55
-2
ECL
59
-3
LYB
44
3
PM
41
2
EOG
62
6
HIG
54
-8
AES
46
2
AAL
16
-13
CAT
55
-2
PH
60
-2
MDLZ
34
4
SJM
19
2
D
58
5
CINF
58
3
O
48
-14
IR
35
-3
MKC
38
2
PNC
59
3
L
67
3
KIM
50
13
ISRG
55
-2
ECL
59
-3
LYB
44
3
PM
41
2
Financhill
Back

Cosmo Pharmaceuticals NV 10K Form

Sell
34

CMOPF
Cosmo Pharmaceuticals NV

Last Price:
$109.00
Seasonality Move:
-11.15%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CMOPF News And Ratings

See the #1 stock for the next 7 days that we like better than CMOPF

CMOPF Financial Statistics

Sales & Book Value

Annual Sales: $117.6M
Cash Flow: $0
Price / Cash Flow: 30.57
Annual Sales: $33.30
Price / Book: 2.32

Profitability

EPS (TTM): -0.25420
Net Income (TTM): $-3.9M
Gross Margin: $54.7M
Return on Equity: 15.06%
Return on Assets: 10.72%

Cosmo Pharmaceuticals NV Earnings Forecast

Key Cosmo Pharmaceuticals NV Financial Ratios

  • The Gross Profit Margin over the past 22 years for CMOPF is 46.53%.
  • The Selling, General & Administrative Expenses for CMOPF have been equal to 25.72% of Gross Profit Margin.
  • The Research & Development expenses have been 30.80% of Revenue.
  • The Net Earning history of CMOPF is -3.35% of Total Revenues.
  • Per Share Earnings over the last 22 years have been positive in 12 years.

Cosmo Pharmaceuticals NV Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: CMOPF
Website: cosmopharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.85
Quick Ratio: 4.48

Price-to-Earnings

Trailing P/E Ratio: 15.6
Forward P/E Ratio: 0

CMOPF Technical Analysis vs Fundamental Analysis

Sell
34
Cosmo Pharmaceuticals NV (CMOPF) is a Sell

Is Cosmo Pharmaceuticals NV a Buy or a Sell?